Monte Rosa Therapeutics
GLUE
56 hedge funds and large institutions have $759M invested in Monte Rosa Therapeutics in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 20 closing their positions.
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
17% more funds holding
Funds holding: 48 → 56 (+8)
8% more capital invested
Capital invested by funds: $705M → $759M (+$54.3M)
3.09% more ownership
Funds ownership: 72.14% → 75.23% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$75.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.4M |
| 3 |
BlackRock
New York
|
+$14.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.7M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.95M |
| 2 |
O
OrbiMed
New York
|
-$7.95M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.17M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$3.4M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.94M |
GLUE Hedge Fund Activity: Q3 2021 in Review
56 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q3 2021, worth a combined $759M — up 7.7% from $705M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new GLUE positions and 20 closed out — a net gain of 8 holders — while 6 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $75.8M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.95M sold.
- 56 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q3 2021, up from 48 in Q2 2021.
- Funds reported $759M of Monte Rosa Therapeutics stock for Q3 2021, up 7.7% quarter-over-quarter.
- 28 funds opened new Monte Rosa Therapeutics positions in Q3 2021 and 20 closed out, a net change of +8 holders.
- The largest Monte Rosa Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $75.8M added.
- The largest Monte Rosa Therapeutics seller in Q3 2021 was Deerfield Management, an estimated $7.95M sold.
Based on aggregated 13F filings for Q3 2021.